Standout Papers

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and e... 2020 2026 2022 2024300
  1. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial (2020)
    Nirav N. Shah, Bryon D. Johnson et al. Nature Medicine

Immediate Impact

2 by Nobel laureates 16 from Science/Nature 75 standout
Sub-graph 1 of 22

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
2024 Standout
2 intermediate papers

Works of Sharon Yim being referenced

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Sharon Yim 330 102 115 7 377
Lauren S. Riley 312 116 94 5 404
Marika Sherman 374 96 76 12 393
Julie Rivers 385 57 110 9 401
Hannah Karlsson 386 131 106 11 425
Martina Schüßler‐Lenz 334 125 97 8 423
Patrick Paczkowski 315 156 109 12 432
David Rushworth 345 102 173 10 413
Ashwini Balakrishnan 338 112 115 7 435
Vania Aikawa 282 102 66 4 345
Hilde Almåsbak 368 207 101 9 437

All Works

Loading papers...

Rankless by CCL
2026